Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke

被引:41
作者
Brdon, Jan [1 ]
Kaiser, Sabine [1 ]
Hagemann, Friederike [1 ]
Zhao, Yi [1 ]
Culman, Juraj [1 ]
Gohlke, Peter [1 ]
机构
[1] Univ Hosp Schleswig Holstein, Inst Pharmacol, D-24105 Kiel, Germany
关键词
angiotensin II; AT(1) receptor; candesartan; cerebral ischaernia; neuroprotection; stroke;
D O I
10.1097/01.hjh.0000254376.80864.d3
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Objective The effects of candesartan treatment starting early (3 h) and delayed (24 h) after middle cerebral artery occlusion (MCAO) with reperfusion was investigated in normotensive rats. Methods Subcutaneous treatment with candesartan (0.3 and 3 mg/kg) or vehicle was initiated 3 or 24 h after the onset of MCAO and continued for seven consecutive days (n = 20 per group and timepoint). Neurological outcome was evaluated daily using two different scoring systems. Infarct and oedema volumes were determined in rats 2 or 7 days after MCAO. Mean arterial, systolic and diastolic blood pressures were recorded before and after the application of candesartan. Results Mean arterial, systolic and diastolic blood pressures were markedly decreased with the high dose, but only moderately decreased with the low dose of candesartan. Vehicle-treated rats showed marked neurological deficits 24 h after MCAO, which gradually improved with time. Candesartan improved neurological outcomes at all timepoints only when treatment was started 3, but not 24 h after MCAO. The infarct volume was reduced on days 2 and 7 after MCAO in rats treated with the low but not the high dose of candesartan. Conclusion The present study demonstrates that only an early but not a delayed onset of treatment with candesartan exerts neuroprotection after focal ischaemia. The degree of neurological impairments did not correlate with the infarct volume, which was reduced only after the low dose of candesartan. The high dose of candesartan failed to reduce the infarct volume, probably because of an excessive blood pressure decrease.
引用
收藏
页码:187 / 196
页数:10
相关论文
共 49 条
[1]
Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats [J].
Ando, H ;
Zhou, J ;
Macova, M ;
Imboden, H ;
Saavedra, JM .
STROKE, 2004, 35 (07) :1726-1731
[2]
RAT MIDDLE CEREBRAL-ARTERY OCCLUSION - EVALUATION OF THE MODEL AND DEVELOPMENT OF A NEUROLOGIC EXAMINATION [J].
BEDERSON, JB ;
PITTS, LH ;
TSUJI, M ;
NISHIMURA, MC ;
DAVIS, RL ;
BARTKOWSKI, H .
STROKE, 1986, 17 (03) :472-476
[3]
Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome [J].
Castillo, J ;
Leira, R ;
García, MM ;
Serena, J ;
Blanco, M ;
Dávalos, A .
STROKE, 2004, 35 (02) :520-526
[4]
Blood pressure and stroke: a continuing debate [J].
Chalmers, John .
JOURNAL OF HYPERTENSION, 2006, 24 (07) :1249-1251
[5]
Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats [J].
Culman, J ;
von Heyer, C ;
Piepenburg, B ;
Rascher, W ;
Unger, T .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 367 (2-3) :255-265
[6]
The renin-angiotensin system in the brain: an update [J].
Culman, J ;
Baulmann, J ;
Blume, A ;
Unger, T .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2001, 2 (02) :96-102
[7]
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[8]
Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats [J].
Dai, WJ ;
Funk, A ;
Herdegen, T ;
Unger, T ;
Culman, J .
STROKE, 1999, 30 (11) :2391-2398
[9]
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats [J].
Engelhorn, T ;
Goerike, S ;
Doerfler, A ;
Okorn, C ;
Forsting, M ;
Heusch, T ;
Schulz, T .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2004, 24 (04) :467-474
[10]
Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection [J].
Fagan, SC ;
Kozak, A ;
Hill, WD ;
Pollock, DM ;
Xu, L ;
Johnson, MH ;
Ergul, A ;
Hess, DC .
JOURNAL OF HYPERTENSION, 2006, 24 (03) :535-539